Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Clinical data, dosing, and costs compared
While the mechanisms differ from tirzepatide, the clinical outcomes are comparable for most patients with type 2 diabetes
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2negative, advanced or metastatic breast cancer: a US food and drug administration pooled analysis
Safety and considerations There is not enough high-quality, modern human safety data to make broad safety claims about DSIP, and that uncertainty is itself part of the clinical picture
US$ 28.40
US$ 22.88
US$ 26.93
